NAT10 and colorectal carcinoma: Our work demonstrated that Remodelin, a specific inhibitor of NAT10, synergizes with anti–PD-1 therapy to inhibit CRC growth by restoring the cytotoxic function of GzmB+ and IFN-γ+ CD8+ T cells.